



EXACT Therapeutics to Present at the Annual International Symposium on Therapeutic Ultrasound (ISTU 2024)

Oslo, Norway, September 18, 2024 - EXACT Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision medicine company utilizing the power of ultrasound to enable targeted drug delivery in oncology, today announced that it will be giving two presentations at the upcoming 23rd Annual International Symposium on Therapeutic Ultrasound, taking place September 19-22, 2024, in Taipei, Taiwan. The company will be giving a virtual company presentation and in addition, will be presenting a poster on Mechanistic Insights of Acoustic Cluster Therapy (ACT®), EXACT's unique ultrasound mediated oncology therapy.

Details of the company- and poster presentations are as follows:

Virtual Company presentation

Title: Acoustic Cluster Therapy – clinical translation of a new microdroplet drug delivery technology

- Body Clinical Session on Saturday September 21st at 14:16 (local time) in room 101

Poster presentation

Title: Mechanistic Insights of Acoustic Cluster Therapy (ACT®): Understanding ACT Bubble Creation and Oscillation Behaviour

- Poster Session on Friday September 20th at 15:00 (local time) on first floor of TICC

The company presentation will be made available at the Investors section the Company's website: <https://exact-tx.com/finreports> and the poster will be made available in the Research Papers section: <https://exact-tx.com/publications-1-1> in parallel with the Session.

For further information, please contact:

Per Walday

CEO EXACT Therapeutics

Email: per.walday@exact-tx.com



About EXACT Therapeutics

EXACT is a clinical-stage Norwegian precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to enable or significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com

About ACT®

- ACT is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
- ACT is being tested in the clinic and has released positive interim data. It is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
- Initial focus of the company is oncology. The ACT platform has potential across many therapeutic areas (including CNS, immunotherapy) and product classes.

Forward looking statements:

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.